Data supports fast approval for Roche’s breast cancer drug: FDA staff

(Reuters) – Trial data on Swiss drugmaker Roche’s breast cancer treatment Perjeta supported a faster approval of the drug for use in early stages of the disease, reviewers for the U.S. Food and Drug Administration said on Tuesday. Roche is seeking approval for Perjeta as a neoadjuvant, or initial, treatment for early stage breast cancer patients whose cancer cells contain increased amounts of the HER2 protein. A neoadjuvant treatment is given in the beginning to shrink a tumor before the main treatment. …